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Multidrug resistance is often associated with the (over)expression of drug efflux transporters of the ATP-binding cassette (ABC)
protein family. This minireview discusses the role of one selected ABC-transporter family member, the breast cancer resistance
protein (BCRP/ABCG2), in the (pre)clinical efficacy of novel experimental anticancer drugs, in particular tyrosine kinase inhibitors.
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Cellular drug resistance is a major obstacle in cancer therapy.
Cancer cells can acquire resistance to a single drug, to a class of
cytotoxic or novel targeted drugs or to a broad spectrum of
structurally and functionally unrelated drugs. This latter pheno-
menon is known as multidrug resistance (MDR) and can be
conveyed by several mechanisms including reduced drug uptake,
activation of DNA repair and defective apoptotic pathways. Most
commonly, however, MDR results from the active, ATP-dependent
transport of drugs out of the cell by efflux pumps belonging to
the ATP-binding cassette (ABC) family of transporters (Borst
and Elferink, 2002). For more than 30 years, P-glycoprotein
(P-gp/ABCB1) has been the most studied MDR transporter (for a
comprehensive review, see Gottesman and Ling, 2006). Nowadays,
it is established that also other ABC transporters such as the
multidrug resistance protein 1 (MRP1/ABCC1) (Deeley et al, 2006;
Hooijberg et al, 2006) and the breast cancer resistance protein
(BCRP/ABCG2) (Sarkadi et al, 2006) are involved in MDR. This
minireview highlights some recent and clinically relevant aspects
of the BCRP drug efflux transporter from the perspective of
current cancer chemotherapy, in particular targeted therapy with
tyrosine kinase inhibitors (TKIs).
BCRP
Breast cancer resistance protein is a half transporter member
of the ABCG subfamily (ABCG2) and was first identified by Doyle
et al (1998) in a human breast cancer cell line selected for
doxorubicin resistance in the presence of verapamil, an inhibitor
of P-gp. Overexpression of BCRP is associated with resistance to a
wide range of different anticancer agents including mitoxantrone,
camptothecins, anthracyclines, flavopiridol and antifolates (Table 1)
(Assaraf, 2006; Robey et al, 2007). More recently, BCRP has also
been shown to confer resistance to some purine analogues such as
9-(2-phosphonylmethoxyethyl)adenine and cladribine (Takenaka
et al,2 0 0 7 ) .
Several studies have been dedicated to determine relationships
between the expression of BCRP in human cancers and clinical
outcome for several drugs (summarised in Robey et al, 2007).
Expression of BCRP has been reported in different types of
leukaemia (AML and ALL) and solid tumours. The large variety of
tumour types may have led to a lack of consensus regarding the
impact of BCRP expression on clinical outcome, as some groups
reported a correlation between BCRP expression and poor
treatment response while others found no correlation. Further-
more, different treatment regimens were used for the various
malignancies, adding another complicating factor. It is currently
being appreciated that several additional factors should be
considered to allow more accurate assessments of the role of
BCRP in drug resistance and clinical outcome. These may include
(a) genetic polymorphisms of BCRP that may affect substrate
specificity and hence cross-resistance patterns, (b) regulation of
BCRP expression by intracellular phosphorylation and/or
BCRP promoter methylation and (c) a role for BCRP in the gut
determining bioavailability of several drugs (Robey et al, 2007).
The following sections in this review focus on these aspects in the
context of deciphering the role of BCRP in the efficacy of a specific
class of targeted agents, that is, TKIs.
TKIs
It has been described that several TKIs are able to interact with
members of the ABC family of transporters such as BCRP, P-gp
and MRP1 (Hegedus et al, 2002; Shukla et al, 2007). Most studies
have been focused on the interaction between TKIs and BCRP,
while scarce information is available for the interaction of MRP1 or
other MRPs and these drugs. However, since several controversial
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analyse and discuss some recent data and to further clarify
potential interaction(s) between BCRP and TKIs.
Canertinib
Canertinib (CI-1033) is a HER family TKI that has been shown to
interact with BCRP. Erlichman et al (2001) showed that MDA-MB-
231 cells transfected with BCRP had 4.9-fold lower accumulation of
canertinib than cells transfected with empty vector, suggesting that
canertinib is a substrate for BCRP. In both BCRP-transfected cells
and unselected HCT8 colorectal carcinoma and T98G glioblastoma
cells with endogenous BCRP expression, canertinib sensitised cells
to SN-38 and topotecan. Consistently, canertinib increased the
cellular accumulation of these drugs (Erlichman et al, 2001).
Imatinib
Imatinib mesylate is a TKI of BCR-ABL, platelet-derived growth
factor receptor and stem cell factor/c-kit. Conflicting results have
been published regarding the ability of BCRP to transport this
compound. In one study, overexpression of BCRP in Saos2 cells
did not confer resistance to imatinib, and accumulation and efflux
of this drug were not affected by BCRP expression and ATP
depletion (Houghton et al, 2004), suggesting that imatinib is not a
substrate of BCRP. Rather, imatinib may serve as a potent BCRP
inhibitor thereby enabling reversal of BCRP-mediated resistance to
topotecan and SN-38 (Houghton et al, 2004). Similarly, accumula-
tion of mitoxantrone in primary chronic myeloid leukaemia (CML)
CD34þ cells overexpressing BCRP was significantly increased by
5mM of imatinib, confirming the activity of this TKI as a BCRP
inhibitor (Jordanides et al, 2006). The same authors postulated
that imatinib is not a BCRP substrate, since BCRP inhibition in
CML CD34þ cells neither potentiated the effect of imatinib nor
affected imatinib accumulation in these cells. In contrast, Burger
et al (2004) showed that MCF7/MR and MCF7/AdVp3000 cells,
with overexpression of BCRP, had significantly lower intracellular
imatinib accumulation compared with the parental MCF7 cell line.
Also HEK293 cells transfected with BCRP variants, both wild-type
(Arg at position 482, HEK293/R) and mutants (Gly or Thr at
position 482, HEK293/G and HEK293/T), showed a markedly
decreased imatinib accumulation, which could almost be com-
pletely reversed by the BCRP-specific inhibitor Ko143 (Burger
et al, 2004). Also the specific BCRP inhibitor fumitremorgin C
(FTC) could reverse the two- to three-fold resistance to imatinib of
BCR-ABL-expressing cells transduced and selected to overexpress
BCRP (K562/BCRP-MX10) (Nakanishi et al, 2006). Moreover,
Brendel et al (2007) postulated that imatinib is a BCRP substrate
based on the observations that (a) BCRP-transduced K562 cells
were two- to three-fold resistant to imatinib-induced apoptosis
and that inhibition of BCRP with FTC completely abrogated the
resistant phenotype, (b) imatinib directly interacts with BCRP at
the substrate binding site and stimulates BCRP ATPase activity,
and finally (c) BCRP-transduced cells displayed significantly less
imatinib accumulation. Although this study provides strong
evidence for imatinib as a BCRP substrate, it may also point to
the fact that imatinib transport by BCRP is concentration
dependent since imatinib transport was facilitated only at low
concentrations (o1mM). Confirmative experimental evidence for
this notion was presented by Shukla et al (2007), who reported a
narrow concentration range within which BCRP can transport
TKIs and, in particular, imatinib. Thus, although the controversy
may persist whether or not imatinib is a BCRP substrate, this
hypothesis might help to explain the contradictory results, since
different concentrations of the drug have been used in various
literature reports.
Other interactions besides being a possible substrate or inhibitor
seem to exist, since imatinib itself could attenuate its resistance by
suppressing BCRP expression (Nakanishi et al, 2006). Interest-
ingly, however, imatinib decreased the expression of BCRP only in
K562/BCRP-MX10 cells expressing BCR-ABL, but not in cells
lacking BCR-ABL expression. The underlying mechanism for these
differential responses involved downstream effects of imatinib
inhibition of BCR-ABL, leading to the decreased phosphorylation
of Akt, subsequently leading to reduced BCRP expression
(Nakanishi et al, 2006). This study showed that an active PI3K–
Akt pathway is responsible, at least in part, for maintenance of
BCRP expression (Figure 1). Additionally, the PI3K–Akt signalling
pathway may regulate the cellular localisation of this transporter.
In this context, Mogi et al (2003) showed that Akt inhibition by
LY294002 provoked translocation of Bcrp1 from the plasma
membrane to the cytoplasmic compartment of side population
(SP) cells.
Recent studies suggested that BCRP, along with P-gp, might
limit the brain penetration of imatinib, reinforcing the idea that
this TKI is a BCRP substrate. Breedveld et al (2005) showed that
Table 1 BCRP substrates and polymorphisms
Substrates
Classical anticancer drugs Novel targeted drugs
Mitoxantrone Canertinib (CI-1033)
a
Anthracyclines
b Imatinib
a
Camptothecins Nilotinib
a
Antifolates
b Gefitinib
a
Erlotinib
Flavopiridol
Polymorphisms
c
Variant Amino-acid change Effect
G34A Val12Met (V12M) No change
C376T Gln126stop (Q126T) No active BCRP protein
C421A Gln141Lys (Q141K) Decreased protein levels and drug resistance
Increased gefitinib-associated toxicity (diarrhoea)
Increased imatinib accumulation in vitro, but no changes in the pharmacokinetic parameters of imatinib in vivo
G1322A Ser441Asn (S441N) Decreased protein levels and different subcellular localisation
BCRP¼breast cancer resistance protein.
aCompounds that are simultaneously substrates and inhibitors.
bEfflux of compounds affected by mutation at position 482.
cMore BCRP
SNPs have been described, but no relation with functional activity or protein expression was reported (summarised by Yanase et al, 2006).
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brain penetration and decreased imatinib clearance compared with
wild-type mice. Additionally, they have shown that co-adminis-
tration of BCRP and P-gp inhibitors improved the brain
penetration of the drug in wild-type mice. Similarly, Bihorel et al
(2007) showed that blockade of both P-gp and Bcrp1 significantly
increased the brain penetration of imatinib and its metabolites. Of
note, however, the blood concentration and brain penetration of
imatinib were unaltered in Bcrp1 knockout and wild-type mice.
The authors postulated that a functional P-gp activity in the
blood–brain barrier of Bcrp1 knockout mice might be dominantly
responsible for retaining a similar brain uptake of imatinib as
compared to wild-type animals.
Nilotinib
Nilotinib is a novel BCR-ABL TKI, more potent and selective than
imatinib. Brendel et al (2007) showed that BCRP-overexpressing
K562 cells were two- to three-fold resistant to nilotinib; however,
this was observed only at very low concentrations (10 and 25nM),
suggesting that resistance to nilotinib may not occur at clinically
relevant concentrations. Notwithstanding these facts, the notion
that nilotinib is a substrate for BCRP was supported by
observations that it interacted with the BCRP substrate binding
site, it stimulated the ATPase activity of this transporter and its
accumulation was significantly suppressed in BCRP-transduced
cells. Of further interest, nilotinib appeared to be a more potent
inhibitor of BCRP than imatinib.
Gefitinib
Contradictory data have been published also for the epidermal
growth factor receptor (EGFR) TKI gefitinib, since some authors
describe it as a BCRP substrate, while others classified it as an
inhibitor and not a substrate (Elkind et al, 2005; Nakamura et al,
2005). Most likely, the apparent discrepancy in these results is due
to the selected concentrations of gefitinib used in the different
studies. Elkind et al (2005) showed that low concentrations of
gefitinib (o1mM) significantly activated BCRP-ATPase activity in
isolated membranes of BCRP-expressing mammalian MCF-7/MX
and A431 cells, whereas higher concentrations (41mM) had a
markedly lower stimulatory effect. Consequently, this might
explain the lack of gefitinib transport into vesicles of PC-6/SN2-
5H cells, since a gefitinib concentration of 30mM was used in this
study (Nakamura et al, 2005). These results suggest that, as
discussed above for imatinib, gefitinib might also have a narrow
window, especially in a low concentration range, where its active
transport by BCRP is efficient. Consistent with gefitinib being a
BCRP substrate, BCRP-transduced A431 cells were resistant to
gefitinib compared with the parental cell line (Yanase et al, 2004;
Elkind et al, 2005) and the resistant phenotype was reversed by the
BCRP-specific inhibitor Ko143 (Elkind et al, 2005). Of note,
consistent with EGFR amplification and dependence on EGFR
signalling for survival, A431 cells are highly sensitive to gefitinib,
with IC50 values in the nanomolar range. Conversely, K562 and
P388 cells transduced with BCRP did not show gefitinib resistance
(Yanase et al, 2004). In fact, wild-type K562 and P388 cells are
relatively resistant to gefitinib with IC50 values in the 1–10mM
range being compatible with their lack of inherent EGFR
expression. Consistent with this, we have recently found that
human EGFR-expressing Caco-2 colon carcinoma cells exhibit
gefitinib IC50 values in the 300–600nM range; in these cells, BCRP
overexpression induced gefitinib resistance (Lemos et al, 2006a).
In contrast, MCF-7/MR, with very low EGFR expression, displayed
IC50 values for gefitinib in the 5–10mM range and in these cells
BCRP overexpression was not a determinant of gefitinib resistance
(data not shown). Thus, it has been hypothesised that BCRP is one
of the determinants of gefitinib resistance in cells that express
EGFR and show EGFR-dependent growth (Yanase et al, 2004). In
fact, Elkind et al (2005) have shown that BCRP expression protects
cells from gefitinib-mediated inhibition of EGFR phosphorylation
and subsequent apoptosis. This suggests that BCRP prevents the
action of gefitinib by effluxing this compound from the cell before
it can interact with plasma membrane-associated EGFR. Similar to
canertinib and imatinib, gefitinib is also a BCRP inhibitor and
reverses BCRP-mediated drug resistance both in vitro and in vivo
(Yanase et al, 2004; Nakamura et al, 2005).
Erlotinib
Erlotinib is another EGFR TKI whose interaction with BCRP has
been studied to a lesser extent. Nonetheless, a preliminary study
suggests that erlotinib is also a substrate of BCRP (van Tellingen
et al, 2007). Since both gefitinib and erlotinib can affect
phosphorylation of Akt, downstream of EGFR, this mechanism
may also be involved.
BCRP AND TKI BIOAVAILABILITY
It has been shown that BCRP is highly expressed in the small
intestine and colon, suggesting that this transporter is involved in
the regulation of uptake of substrates from the gastrointestinal
?
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Figure 1 Interaction between TKIs and BCRP. An active PI3K–Akt pathway is apparently important for BCRP expression and localisation in the plasma
membrane. (A) Stimulation of this pathway with EGF, for example, will phosphorylate Akt, leading to BCRP localisation to the plasma membrane. (B) (I)
BCRP can actively efflux TKIs, thus inducing resistance to these drugs. However, BCRP-mediated TKIs resistance might be abrogated by TKIs inhibition of the
PI3K–Akt pathway, which can lead to (II) BCRP relocalisation to the intracellular compartment and/or (III) decreased BCRP expression.
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substrates from mucosal cells back to lumen. Since all discussed
TKIs are orally active compounds, BCRP might limit their activity
not only by mediating extrusion and inducing resistance in the
tumour cells, but also by reducing their oral bioavailability. Using
Caco-2 cells as an in vitro model for intestinal drug transport,
Burger et al (2005) found that continuous exposure to imatinib
upregulates the expression of BCRP and P-gp, which resulted in a
decreased intracellular accumulation of imatinib. We have also
recently shown that BCRP expression in Caco-2 cells is upregu-
lated under folate-deficient conditions (Lemos et al, 2006b).
Folates might also affect the subcellular localisation of BCRP
(Ifergan et al, 2005). Thus, modulation of expression of BCRP and
other ABC transporters in the gut might have a crucial role in the
bioavailability of orally administered drugs.
BCRP VARIANTS
Disparities in the transport of rhodamine 123 among BCRP-
overexpressing cell lines led to the identification of a mutational
hot spot located in codon 482 where a single amino-acid change
had occurred (Robey et al, 2007). Wild-type BCRP, with an
arginine at position 482 (R482), facilitated efficient transport of
mitoxantrone, but not rhodamine 123 or doxorubicin. In contrast,
cells carrying a glycine (R482G) or a threonine (R482T) at position
482 were able to transport rhodamine 123 and doxorubicin, while
also maintaining their ability to transport mitoxantrone. The BCRP
variants were found in drug-resistant S1-M1-80 (R482G) and MCF-
7 AdVp3000 (R482T) but not in the parental S1 and MCF-7 cell
lines, suggesting that these were acquired mutations resulting from
drug selection. Inside-outside vesicles from these cell lines do not
influx methotrexate. Hence these R482G cells were not resistant
compared to cells with wild-type BCRP when continuously
exposed to methotrexate (Chen et al, 2003). However, when a
short 4h exposure was used, the mutant R482G was highly
resistant to methotrexate (Assaraf, 2006). This discrepancy can
possibly be explained by the use of vesicles in which only uptake of
native methotrexate was measured, while in intact cells, conti-
nuous exposure to methotrexate leads to massive polyglutamyla-
tion, preventing efflux in both wild-type and mutant cells. At a
short exposure, polyglutamylation is less extensive, leading to
efflux of the parent drug and lower polyglutamylates. Such studies
show that vesicles are excellent models to study transport, but do
not provide an insight into the role of cellular metabolism and
transport.
It is now clear that BCRP mutations have a high impact on the
substrate specificity of this transporter and that cells harbouring
these mutations are cross-resistant to a wider variety of
chemotherapeutic agents (Assaraf, 2006). However, BCRP muta-
tions at amino acid 482 have not yet been found in clinical
samples, suggesting that their relevance for clinical drug resistance
may be limited.
Several single nucleotide polymorphisms (SNP) in the ABCG2
gene have been reported that might have an important impact on
BCRP protein expression and function (Table 1). A nonsynon-
ymous SNP C421A resulting in a glutamine to lysine amino-acid
change at position 141 (Q141K) has been associated with markedly
decreased levels of BCRP protein expression and also low levels
of drug resistance. Nonetheless, cross-resistance patterns were
similar for the wild type and the Q141K BCRP variant, suggesting
that this polymorphism does not affect substrate recognition of
BCRP (Imai et al, 2002). More recently, Cusatis et al (2006)
reported that the C421A polymorphism was statistically signifi-
cantly associated with the occurrence of diarrhoea in a cohort of
173 Caucasian patients with non-small-cell lung cancer receiving
treatment with oral gefitinib. In the group of 16 patients carrying
at least one A421 allele, 7 (44%) developed diarrhoea, while only 12
out of 108 (12%) patients had diarrhoea among the group carrying
the wild-type genotype. The reduced protein levels and altered
ATPase activity of the BCRP C421A variant might affect the oral
absorption and/or elimination pathways of gefitinib and thereby
increase the steady-state gefitinib plasma concentrations leading to
diarrhoea. In contrast, Gardner et al (2006) did not find significant
differences in the pharmacokinetic parameters of imatinib in vivo
between 16 patients heterozygous for the C421A SNP compared
with 66 patients harbouring the wild-type sequence. This result
was unexpected, since the authors showed that HEK293 cells
transfected with wild-type BCRP accumulated significantly less
imatinib than HEK293 cells transfected with the C421A BCRP
variant, despite similar levels of protein expression. In a Japanese
population, 57 out of 124 patients expressed the A421 allele,
indicating that the A421 allele frequency in this population is quite
high (Imai et al, 2002). The C421A variant seems less frequent in
other ethnic groups (Yanase et al, 2006). Kondo et al (2004) also
observed that the C421A SNP was associated with a 60–70%
lower protein expression compared to that of the wild-type.
Another SNP, G1322A (S441N), showed even lower levels of
protein expression. Contrary to the wild-type and all other BCRP
variants that had an apical membrane localisation, this latter BCRP
variant was expressed intracellularly, suggesting that BCRP SNPs
might also affect its cellular localisation. Another SNP, the C376T,
replaces glutamine by a stop codon at position 126 (Q126T), and
was found in 3 out of the 124 Japanese population (Imai et al,
2002). Despite its low frequency, this C376T polymorphism may
have a higher impact than the C421A polymorphism because no
active BCRP protein can be expressed from this gene. Finally,
another BCRP SNP found in this Japanese population, G34A,
which replaces valine by methionine at position 12 (V12M),
showed similar protein expression and drug resistance levels as the
wild-type (Imai et al, 2002).
From these studies, it is clear that BCRP expression and
localisation are regulated at different levels, in which various
polymorphisms seem to play an important role.
BCRP IN STEM CELLS
Stem cells have the unique ability of self-renewal and can
differentiate into a variety of specialised cell types. The SP
phenotype, which is characterised by the ability to transport the
fluorescent dye Hoechst 33342, has been identified as a
characteristic feature of haematopoietic stem cells.
Owing to the ability of P-gp to transport Hoechst, initially this
transporter was thought to be responsible for the SP phenotype.
However, since mice deficient in P-gp had a normal number of
bone marrow SP cells, it was concluded that P-gp is not required
for the SP phenotype. A more detailed examination of other ABC
transporters in bone marrow cells of P-gp knockout mice revealed
high levels of Bcrp1 mRNA and distinct levels of Mrp1, Mrp3 and
Mrp4 mRNA (Zhou et al, 2001). The notion that only BCRP can
efflux Hoechst demonstrated that this transporter was dominantly
associated with the SP phenotype, which was further confirmed by
BCRP transfection in bone marrow cells causing significant
expansion of cells bearing the SP phenotype (Zhou et al, 2001).
Also in Bcrp1/Mdr1a/1b triple knockout mice, it was shown that
Bcrp1, but not Mdr1a/1b, is responsible for the SP phenotype in
the bone marrow, while both transporters are required for the SP
phenotype in the mammary gland (Jonker et al, 2005). It has now
been demonstrated that SP cells are present in several tumour
samples, possess stem cell-like properties, overexpress BCRP and
possess inherent drug resistance (Haraguchi et al, 2006).
Consistently, BCRP overexpression was reported on primary
CML CD34þ cells (Jordanides et al, 2006). Imatinib is efficiently
used in the clinical treatment of BCR-ABL-driven CML, but
possible BCRP-mediated imatinib resistance would naturally affect
BCRP and targeted therapy
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stem cells with potent and specific inhibitors might constitute an
important strategy to eliminate or reduce the tumour stem cell
population and improve the efficacy of targeted therapy.
CONCLUSION
Overexpression of BCRP can provoke MDR in cancer cells,
although its role in clinical drug resistance remains unclear
(Robey et al, 2007). Several TKIs have recently been shown to
interact with BCRP; thus, BCRP can confer resistance to these
drugs, both at the tumour cell level and by decreasing their oral
bioavailability. A hot spot mutation at amino acid 482 and several
SNPs have been described for the BCRP gene, which may affect
substrate specificity, expression and function of this transporter.
These genetic variations must, therefore, be taken into account
when targeting BCRP to reverse/modulate drug resistance. The
expression of BCRP in SP cells, and in particular SP of tumour
cells, might also be of great interest in the development of new
anticancer strategies.
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